GTS Alliance Gives Mochida A Cell Therapy Buy-In
Rare GI Disorder Focus
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
You may also be interested in...
Antibody-focused MabGenesis is building on a technology platform it says can efficiently produce highly targeted antibodies against challenging targets. The Japanese venture is looking for both its first major deal and potentially an IPO within the next five years.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.